The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis
Abstract
Purpose: Analysis of patients with late relapse (LR) of germ cell tumor (GCT) with reports on clinical characteristics, outcomes, and molecular and cytogenetic features. Patients and Methods: Eighty-three patients evaluated at Indiana University from 1993 through 2000 for relapse of GCT more than 2 years from initial therapy were reviewed. Available specimens were investigated for expression of the transcription regulator FoxD3 and apurinic/apyrimidinic endonuclease and the presence of chromosome 12 abnormalities. Results: Median interval from initial presentation to LR was 85 months. Forty-three of 49 LR patients who underwent surgery were rendered disease free (NED), and 20 (46.5%) remain continuously NED. Thirty-two patients received chemotherapy, but only six (18.8%) obtained a complete remission. Five of these patients remain continuously NED after chemotherapy alone, including three who were chemotherapy naïve. Eighteen of these 32 patients were successfully rendered NED by postchemotherapy surgery, and 12 remain continuously NED. Two patients continue on observation with no treatment for their LR. Overall, 69 of the 81 treated patients (85.2%) ultimately achieved an NED state, and 38 (46.9%) remain continuously NED with median follow-up from LR therapy of 24.5 months (range, 1 to 83 months), whereas nine other patients are currently NED after therapy for subsequent relapses. Because of the small numbers of specimens tested, we were unable to draw any definitive conclusions from the molecular and cytogenetic analyses. Conclusion: GCT patients require lifetime follow-up. At the time of LR, surgical resection alone remains our preferred therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1
Hromas, R., Orazi, A., Neiman, R., Maki, R., Van Beveran, C., Moore, J., & Klemsz, M. (1993) · Blood · doi:10.1182/blood.v82.10.2998.2998 · Cited by 216
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Guidelines on Testicular Cancer: 2015 Update
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., Horwich, A., Laguna, M. P., Nicolai, N., & Oldenburg, J. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.044 · Cited by 670
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Metadata
- Authors
- George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., Gobbett, T. A., Heiber, D. J., Heerema, N. A., Ramsey, H. C., Thurston, V. C., Jung, S.-H., Shen, J., Finch, D. E., Kelley, M. R., & Einhorn, L. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 113-122
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1993989236
- Cited by
- 166
- References
- 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis. https://app.cochat.ai/papers/10.1200/jco.2003.03.019
- The paper
- George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., Gobbett, T. A., Heiber, D. J., Heerema, N. A., Ramsey, H. C., Thurston, V. C., Jung, S.-H., Shen, J., Finch, D. E., Kelley, M. R., & Einhorn, L. H. (2003). Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.03.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.